Amicus Therapeutics Inc

NASDAQ:FOLD   3:01:41 PM EDT
18.65
+0.17 (+0.92%)
Regulatory, Earnings Announcements

Amicus Therapeutics Announces Additional Positive Interim Clinical Data For Cln6 Batten Disease Gene Therapy

Published: 10/13/2020 00:35 GMT
Amicus Therapeutics Inc (FOLD) - Amicus Therapeutics Announces Additional Positive Interim Clinical Data for Cln6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society.
Amicus Therapeutics Inc - Interim Safety Data Shows Treatment With At-gtx-501 Was Generally Well Tolerated.
Amicus Therapeutics - Regulatory Interactions for At-gtx-501 Are Ongoing, Co Expects to Give Feedback on Path Forward in 2021.
Amicus Therapeutics Inc - Majority of Adverse Events Were Mild and Unrelated to Treatment.
Amicus Therapeutics Inc - No Pattern of Adverse Events Related to Aav Or Cln6 Immunogenicity Was Observed.
Amicus - Interim Results Show Investigational Gene Therapy Has Potential to Slow Neurological Disease Progression in Children With Cln6 Batten Disease.
Revenue is expected to be $64.74 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $69.15 Million
Next Quarter EPS Guidance is expected to be -$0.19

More details on our Analysts Page.